<DOC>
	<DOC>NCT01825980</DOC>
	<brief_summary>To evaluate the antiviral activity of 3 days of BZF961. To determine safety and tolerability of BZF961 in HCV patients. To evaluate pharmacokinetics of BZF961 in HCV patients.</brief_summary>
	<brief_title>Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Written informed consent must be obtained before any assessment is performed Male &amp; female treatment naive subjects, age 1860 years of age with Hepatitis C genotype1. Subjects must weight at least 50kg to participate in the study, and must have a body mass index (BMI) within the range of 1836 kg/m2 Able to communicate well with the investigator, to understand and comply with the study requirements. Use of other investigational drugs at the time of enrollment, or within 30 days or 5 halflives of enrollment, whichever is longer: or longer if required by local regulations, and for any other limitation of participation in an investigational trial based on local regulations. Subjects that were previously treated for HCV infection.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>